NCT00746226|CompletedPhase 1/2
Probiotics for Birch Pollen Allergy
Probiotic Intervention for Children With Birch Pollen Allergy
Loading search results
Probiotic Intervention for Children With Birch Pollen Allergy
Sponsor study identifier
interventional
47
1 country
1
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2006
Actual (reported)Study Completion
February 2007
Actual (reported)Birch pollen allergy is one of the most common forms of respiratory allergy in the Nordic countries. Treatment consists of antihistamine use. Specific probiotic strains have been observed to modulate the immune system. Since the body has a common mucosal immune system; it was hypothesised that consumption of probiotics may affect also the respiratory mucosal immune response and hence affect respiratory allergy. Earlier studies with probiotics had been unable to show improvements in adults with pollen allergy. It was therefore hypothesised that children, who's immune system is not yet fully developed, might be better targets.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
June 2006
Actual (reported)February 2007
Actual (reported)September 2, 2008
Actual (reported)September 3, 2008
Actual (reported)Birch pollen allergy symptoms
March/April and June
Nasal Eosinophilia
April/May and June
Change in microbiota composition
April/May and June
Cytokine profile from serum
April/May and June
Faecal recovery of administered probiotics
April/May and June
Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
Numbers 612-624 and 800-811 Microcrystalline cellulose
Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
Microcrystalline cellulose As capsule which could be opened
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Turku University Central Hospital
Turku, 20250, Finland
Arthur C Ouwehand, PhD
Danisco
47 participants (actual enrollment reported by the registry).
First Submitted
September 2, 2008
First Posted
September 3, 2008
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
June 2006
Actual (reported)Study Completion
February 2007
Actual (reported)Last Updated
September 3, 2008
Record last verified: 2008-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: